Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E₂ receptor EP2

Bibliography

• DeWitt DL. Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 1999;55(4):625-31
   PubMed Web of Science ®Google Scholar
• Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002;53:35-57
   PubMed Web of Science ®Google Scholar
• Ganesh T. Prostanoid receptor EP2 as a therapeutic target. J Med Chem 2014;57(11):4454-65
   PubMed Web of Science ®Google Scholar
• Jiang J, Dingledine R. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Trends Pharmacol Sci 2013;34(7):413-23
   PubMed Web of Science ®Google Scholar
• Kawahara K, Hohjoh H, Inazumi T, et al. Prostaglandin E-induced inflammation: Relevance of prostaglandin E receptors. Biochim Biophys Acta 2015;1851(4):414-21
   PubMed Web of Science ®Google Scholar
• Hirata T, Narumiya S. Prostanoid receptors. Chem Rev 2011;111(10):6209-30
   PubMed Web of Science ®Google Scholar
• Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79(4):1193-226
   PubMed Web of Science ®Google Scholar
• Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000;43(5):978-87
   PubMed Web of Science ®Google Scholar
• Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000;59(4):957-80
   PubMed Web of Science ®Google Scholar
• Rojas A, Jiang J, Ganesh T, et al. Cyclooxygenase-2 in epilepsy. Epilepsia 2014;55(1):17-25
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289(21):2819-26
   PubMed Web of Science ®Google Scholar
• Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer’s disease anti-inflammatory prevention trial. Alzheimers Dement 2011;7(4):402-11
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006;60(1):22-31
   PubMed Web of Science ®Google Scholar
• Cannon CP, Cannon PJ. COX-2 inhibitors and cardiovascular risk. Science 2012;336(6087):1386-7
   PubMed Web of Science ®Google Scholar
• Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004;306(5703):1954-7
   PubMed Web of Science ®Google Scholar
• Grosser T, Yu Y, Fitzgerald GA. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu Rev Med 2010;61:17-33
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang M, Yu Y, et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 2006;116(5):1391-9
   PubMed Web of Science ®Google Scholar
• Liang X, Wang Q, Hand T, et al. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer’s disease. J Neurosci 2005;25(44):10180-7
   Google Scholar
• Liang X, Wang Q, Shi J, et al. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol 2008;64(3):304-14
   Google Scholar
• Andreasson K. Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat 2010;91(3-4):104-12
   PubMed Web of Science ®Google Scholar
• Bastien L, Sawyer N, Grygorczyk R, et al. Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype. J Biol Chem 1994;269(16):11873-7
   Google Scholar
• McCullough L, Wu L, Haughey N, et al. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 2004;24(1):257-68
   PubMed Web of Science ®Google Scholar
• Prasanna G, Carreiro S, Anderson S, et al. Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma. Exp Eye Res 2011;93(3):256-64
   Google Scholar
• Jin J, Shie FS, Liu J, et al. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J Neuroinflammation 2007;4:2
   Google Scholar
• Donnini S, Finetti F, Solito R, et al. EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. FASEB J 2007;21(10):2418-30
   Google Scholar
• Kabashima K, Nagamachi M, Honda T, et al. Prostaglandin E2 is required for ultraviolet B-induced skin inflammation via EP2 and EP4 receptors. Lab Invest 2007;87(1):49-55
   Google Scholar
• Kamiyama M, Pozzi A, Yang L, et al. EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene 2006;25(53):7019-28
   Google Scholar
• Banu SK, Lee J, Speights VOJr, et al. Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms. Mol Endocrinol 2009;23(8):1291-305
   PubMedGoogle Scholar
• Jiang J, Quan Y, Ganesh T, et al. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc Natl Acad Sci USA 2013;110(9):3591-6
   PubMed Web of Science ®Google Scholar
• Jiang J, Dingledine R. Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J Pharmacol Exp Ther 2013;344(2):360-7
   PubMed Web of Science ®Google Scholar
• Jiang J, Ganesh T, Du Y, et al. Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto. US02014/179750 A1; 2014
   Google Scholar
• Jiang J, Ganesh T, Du Y, et al. Preparation of indole and benzimidazole derivatives as prostaglandin receptor EP2 antagonists. WO2012/177618 A1; 2012
   Google Scholar
• Buchmann B, Brauer N, Koppititz M, et al. Diaminopyrimidines as modulators of the EP2 receptor. WO2008/152093 A3; 2008
   Google Scholar
• Buchmann B, Bräuer N, Koppitz M, et al. BSP. 5,6-Substituted benzamide-derivative as modulators of EP2 receptor European patent. EP2149 552 A1; 2008
   Google Scholar
• Braeuer N, Buchmann B, Koppitz M, et al. N-(1-phthalazin-1-ylpiperidin-4-yl)amides as EP2 receptor modulators. WO02008/28689 A1; 2008
   Google Scholar
• Buchmann B, Braeuer N, Koppitz M, et al. Thienopyrimidylamines as modulators of the EP2 receptor. WO2009/007422 A1; 2009
   Google Scholar
• Dack KN, Skerratt SE, Yeap SK. Azetidine derivatives and their use as prostaglandin E2 antagonists. WO2008/139287 A1; 2008
   Google Scholar
• Koppitz M, Lindenthal B, Antonious Ter L, et al. Dérivés de n-(indol-3-ylalkyl)-(hétéro)arylamide comme modulateurs du récepteur. WO2010/012397 A1; 2010
   Google Scholar
• Ganesh T, Jianxiong J, Dingledine R. Development of second generation EP2 antagonists with high selectivity. Eur J Med Chem 2014;82:521-35
   PubMed Web of Science ®Google Scholar
• Ganesh T, Jiang J, Yang MS, Dingledine R. Lead optimization studies of cinnamic amide EP2 antagonists. J Med Chem 2014;57(10):4173-84
   PubMed Web of Science ®Google Scholar
• Jiang J, Ganesh T, Du Y, et al. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc Natl Acad Sci USA 2012;109(8):3149-54
   PubMed Web of Science ®Google Scholar
• Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1(1):11-21
   PubMed Web of Science ®Google Scholar
• Loh JK, Hwang SL, Lieu AS, et al. The alteration of prostaglandin E2 levels in patients with brain tumors before and after tumor removal. J Neurooncol 2002;57(2):147-50
   Google Scholar
• Murakami M, Kudo I. Prostaglandin E synthase: a novel drug target for inflammation and cancer. Curr Pharm Des 2006;12(8):943-54
   Google Scholar
• Kawamori T, Uchiya N, Sugimura T, Wakabayashi K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003;24(5):985-90
   Google Scholar
• Hizaki H, Segi E, Sugimoto Y, et al. Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). Proc Natl Acad Sci USA 1999;96(18):10501-6
   Google Scholar
• Kennedy CR, Zhang Y, Brandon S, et al. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 1999;5(2):217-20
   PubMed Web of Science ®Google Scholar
• Savonenko A, Munoz P, Melnikova T, et al. Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor. Exp Neurol 2009;217(1):63-73
   Google Scholar
• Yang H, Zhang J, Breyer RM, Chen C. Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor. J Neurochem 2009;108(1):295-304
   PubMed Web of Science ®Google Scholar
• Serrano GE, Lelutiu N, Rojas A, et al. Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. J Neurosci 2011;31(42):14850-60
   PubMed Web of Science ®Google Scholar
• Johansson JU, Pradhan S, Lokteva LA, et al. Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia. J Neurosci 2013;33(40):16016-32
   Google Scholar
• Johansson JU, Woodling NS, Wang Q, et al. Prostaglandin signaling suppresses beneficial microglial function in Alzheimer’s disease models. J Clin Invest 2015;125(1):350-64
   Google Scholar
• Shie FS, Breyer RM, Montine TJ. Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. Am J Pathol 2005;166(4):1163-72
   PubMed Web of Science ®Google Scholar
• Shie FS, Montine KS, Breyer RM, Montine TJ. Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia 2005;52(1):70-7
   Google Scholar
• Shie FS, Montine KS, Breyer RM, Montine TJ. Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to neurons. Brain Pathol 2005;15(2):134-8
   Google Scholar
• Ganesh T, Jiang J, Shashidharamurthy R, Dingledine R. Discovery and characterization of carbamothioylacrylamides as EP selective antagonists. ACS Med Chem Lett 2013;4(7):616-21
   PubMed Web of Science ®Google Scholar
• af Forselles KJ, Root J, Clarke T, et al. In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP(2) receptor antagonist. Br J Pharmacol 2011;164(7):1847-56
   Google Scholar
• Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 2004;17(1):3-16
   PubMed Web of Science ®Google Scholar
• Stepan AF, Walker DP, Bauman J, et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 2011;24(9):1345-410
   PubMed Web of Science ®Google Scholar
• Abramovitz M, Adam M, Boie Y, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 2000;1483(2):285-93
   PubMed Web of Science ®Google Scholar